News Breaks |
|
|
| March 4, 2013 |
| 06:55 EDT |  | GILD | Gilead data likely to raise investor interest in HCV drug, says Piper Jaffray
After Gilead released initial data on the combination trial of simeprevir plus sofosbuvir for HCV, Piper Jaffray expects investor interest in the treatment to increase following the data. The firm thinks the combination could provide a near-term catalyst for the stock and enable Gilead to beat consensus 2014 and 2015 revenue estimates. The firm thinks the stock will advance further heading into Q2 and it maintains an Overweight rating on the shares. |
|
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| June 18, 2013 |
| 07:28 EDT |  | GILD | Wells Faro to host a conference
 Subscribe for More Information |
|
| June 17, 2013 |
| 16:00 EDT |  | GILD | Options Update; June 17, 2013
Subscribe for More Information |
|
| 06:25 EDT |  | GILD | Gilead reports interim Phase 2 data for Idelalisib
Gilead announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with a median duration of response at this interim analysis of 11.9 months. The most common Grade ≥3 adverse event was diarrhea . Grade ≥3 transaminase elevations were reported via central laboratory testing in 13% of patients; Grade ≥3 neutropenia occurred in 26% of patients. Sixteen percent of patients discontinued due to adverse events. |
|
| June 13, 2013 |
| 10:05 EDT |  | GILD | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:33 EDT | | GILD | Gilead upgraded to Buy from Hold at Argus
Subscribe for More Information |
|
| June 10, 2013 |
| 07:40 EDT | | GILD | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information |
|
| June 7, 2013 |
| 17:21 EDT | | GILD | Gilead announces U.S. FDA priority review designation for Sofosbuvir
Subscribe for More Information |
|
| June 6, 2013 |
| 09:07 EDT | | GILD | Gilead Sofosbuvir likely to be granted priority review, says RBC Capital
Subscribe for More Information |
|
| 08:27 EDT | | GILD | Bernstein's biotech analysts hold an analyst/industry conference call
Subscribe for More Information |
|
|
|
|
|
